Corbus Pharmaceuticals
CRBP
30 hedge funds and large institutions have $5.26M invested in Corbus Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 36 closing their positions.
6,400% more call options, than puts
Call options by funds: $260K | Put options by funds: $4K
298% more capital invested
Capital invested by funds: $1.32M → $5.26M (+$3.94M)
17.04% more ownership
Funds ownership: 0.32% → 17.36% (+17%)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
52% less funds holding
Funds holding: 63 → 30 (-33)
89% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$783K |
| 2 |
SCM
Sio Capital Management
New York
|
+$656K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$195K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$160K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$59.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$63K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$49.5K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.9K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$31K |
| 5 |
BlackRock
New York
|
-$27.8K |
CRBP Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2023, worth a combined $5.26M — up 298% from $1.32M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CRBP and 4 opened new positions — a net loss of 32 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Ikarian Capital, adding an estimated $783K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $63K sold.
- 30 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2023, down from 63 in Q4 2022.
- Funds reported $5.26M of Corbus Pharmaceuticals stock for Q1 2023, up 298% quarter-over-quarter.
- 4 funds opened new Corbus Pharmaceuticals positions in Q1 2023 and 36 closed out, a net change of -32 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2023 was Ikarian Capital, an estimated $783K added.
- The largest Corbus Pharmaceuticals seller in Q1 2023 was Two Sigma Investments, an estimated $63K sold.
Based on aggregated 13F filings for Q1 2023.